{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000844","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.212577+00:00","generated_at":"2026-06-20T19:00:23.499475+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ZyVersa appoints Sapirstein, Freitag, and Rupalla to board post-business combination","bullets":["ZyVersa appoints James Sapirstein (FWBI CEO), Gregory Freitag (PDSB board), and Katrin Rupalla to its board effective Jan 5, 2023.","Appointments fill three vacancies from the Dec 12, 2022 business combination with Larkspur Health Acquisition Corp.","Sapirstein to serve on Compensation & Nominating Committees; receives $40k annual retainer plus $11.5k committee fees.","Freitag to chair Audit and serve on Nominating Committee; receives $40k retainer plus $22.5k committee fees.","Rupalla to chair Nominating Committee; receives $40k retainer plus $8k; all receive option grants under 2022 Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000844","json":"https://secwatch.observer/filing/0001493152-23-000844.json","markdown":"https://secwatch.observer/filing/0001493152-23-000844.md","text":"https://secwatch.observer/filing/0001493152-23-000844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:00:23.499475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53af1aca40","claim":"James Sapirstein was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bcb0e80a92","claim":"Gregory Freitag was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eb4a38e999","claim":"Katrin Rupalla was appointed as Director at ZyVersa Therapeutics, Inc..","evidence_excerpt":"On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}